What the FDA labels say about taking them together
Axitinib and sorafenib
Axitinib's FDA label of March 12, 2026 names sorafenib in its warnings and precautions section; the sorafenib label PlainMeds reads does not name axitinib.
Check it at the source: the axitinib FDA label on DailyMed (effective March 12, 2026, U.S. Pharmaceuticals); the sorafenib FDA label on DailyMed (effective August 28, 2023, Bayer HealthCare Pharmaceuticals Inc.).
What does the axitinib label say about sorafenib?
Axitinib label, warnings and precautionsIn patients who had thyroid stimulating hormone (TSH) <5 μU/mL before treatment, elevations of TSH to ≥10 μU/mL occurred in 79/245 patients (32%) receiving INLYTA and 25/232 patients (11%) receiving sorafenib [see Adverse Reactions (6.1) ].
Source: FDA drug label (INLYTA), NDA202324 (Pf Prism Cv), as published by U.S. Pharmaceuticals, effective March 12, 2026 (SPL set 8a903e31-936e-4ed7-8a59-59f32374f338), via openFDA; the full label on DailyMed
What does the sorafenib label say about axitinib?
Sorafenib's label (effective August 28, 2023) does not name axitinib in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Nexavar), Bayer HealthCare Pharmaceuticals Inc., effective August 28, 2023 (SPL set b50667e4-5ebc-4968-a646-d605058dbef0), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Axitinib | Sorafenib | |
|---|---|---|
| Labeled for | n/a | n/a |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once